| Item Type: | Article |
|---|---|
| Title: | Second-line therapy in refractory pancreatic cancer. results of a phase II study |
| Creators Name: | Pelzer, U., Stieler, J., Roll, L., Hilbig, A., Doerken, B., Riess, H. and Oettle, H. |
| Abstract: | BACKGROUND: This phase II trial investigated the efficacy and safety of oxaliplatin (O), 5-fluorouracil (5-FU), and folinic acid (FA) (OFF) as second-line treatment for patients with metastatic pancreatic adenocarcinoma after failure of first-line gemcitabine treatment. PATIENTS AND METHODS: 37 patients with confirmed progressive disease on gemcitabine therapy were treated with OFF (O 85 mg/m(2) days 8, 22; FA 500 mg/m(2), followed by 5-FU 2,600 mg/m(2) days 1, 8, 15, 22) every 6 weeks. Patients were treated on an outpatient basis and remained on treatment until disease progression. RESULTS: All patients were assessable for toxicity and effectiveness. We observed moderate hematotoxicity, the most common non-hematologic toxicity was neurotoxicity. A total of 12 patients had grade 3 nonhematologic toxicities: nausea and vomiting (4 patients), reversible neurotoxicity (5 patients), and diarrhea (3 patients). No grade 4 toxicities were observed. Median time to progression was 12 (1-125) weeks. Survival in second line was 22 (4-326+) weeks. Overall disease control rate was 49% (complete remission = 3%; partial remission = 3%; stable disease > 12 weeks = 43%). CONCLUSIONS: This regimen is feasible and active with an acceptable toxicity profile; it can be safely administered in an outpatient setting. There is an urgent need for further investigation in phase III trials. |
| Keywords: | Pancreatic Cancer, Salvage Therapy, Oxaliplatin, Infusional 5-FU |
| Source: | Onkologie |
| ISSN: | 0378-584X |
| Publisher: | Karger |
| Volume: | 32 |
| Number: | 3 |
| Page Range: | 99-102 |
| Date: | March 2009 |
| Official Publication: | https://doi.org/10.1159/000197769 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page


Tools
Tools

